Welcome to our dedicated page for Definitive Healthcare SEC filings (Ticker: DH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Definitive Healthcare Corp. filings document the regulatory disclosures of a public healthcare data and analytics software company. Recent Form 8-K reports furnish quarterly and annual financial-result releases covering revenue, net loss, adjusted profitability measures, cash flow, guidance, and impairment-related disclosures tied to the company’s subscription-based commercial intelligence platform.
The filing record also includes definitive proxy materials for annual stockholder matters, board elections, executive compensation, equity awards, and governance practices. Other material-event filings document board and committee composition changes, executive-role and compensation arrangements, and the termination of a nominating agreement affecting director-designation rights.
Definitive Healthcare Corp. CEO Kevin Coop reported a tax-related share disposition tied to vested restricted stock units. On this Form 4, the issuer withheld 37,593 shares of Class A common stock at $0.80 per share to cover Coop’s tax withholding obligations upon RSU settlement. This was not an open-market sale, and after the withholding, Coop directly owns 4,975,229 shares of Class A common stock.
Definitive Healthcare Corp. reported that Chief Legal Officer Jonathan Paris had shares withheld to cover taxes tied to equity compensation. The issuer withheld 30,591 shares of Class A Common Stock at $0.80 per share to satisfy his tax withholding obligations upon vesting and settlement of previously reported RSUs. After this non-market tax-withholding disposition, Paris directly holds 872,263 shares of Class A Common Stock.
Definitive Healthcare Corp. has been notified by Nasdaq that its common stock no longer meets the $1.00 per share minimum bid price required for continued listing on the Nasdaq Global Select Market. The deficiency is based on 30 consecutive business days from May 6, 2026 to June 17, 2026.
The company has 180 calendar days, until December 15, 2026, to regain compliance. Nasdaq will deem the company compliant if the closing bid price is at least $1.00 per share for a minimum of ten consecutive business days, or longer if Nasdaq requires.
If the company does not regain compliance in this initial period, it may qualify for an additional 180-day period by meeting other Nasdaq Capital Market initial listing standards and potentially using actions such as a reverse stock split. The notice does not immediately affect trading, and the stock will continue to trade under the symbol DH while the company evaluates its options.
Hamood Samuel A reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. director Samuel A. Hamood received a grant of 189,190 restricted stock units, each representing one share of Class A Common Stock at no cash cost. These RSUs vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Following this award, Hamood directly holds 289,396 Class A shares and has an additional 51,582 shares reported as indirectly held through AMHAM DH LLC.
Stephenson Scott G reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that director Scott G. Stephenson received a grant of 189,190 shares of Class A Common Stock in the form of restricted stock units. Each RSU represents a contingent right to one share and will vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting, subject to his continued service. Following this award, Stephenson directly holds 313,314 shares of Class A Common Stock.
Winters Kathleen A reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that director Kathleen A. Winters received a grant of 189,190 restricted stock units (RSUs) of Class A Common Stock. The award carries no purchase price and increases her direct holdings to 308,982 shares. These RSUs vest on the earlier of June 4, 2027 or the company’s next annual meeting of stockholders, assuming she continues in service until that vesting date. This is a compensation-related equity grant rather than an open-market transaction.
Chilukuri Sastry reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. director Chilukuri Sastry received an equity grant of 189,190 shares of Class A Common Stock in the form of restricted stock units. These RSUs carry no purchase price and increase his direct holdings to 315,984 shares after the award.
Each RSU represents a contingent right to receive one share of Class A Common Stock. The units vest on the earlier of June 4, 2027 or the date of the company’s next annual stockholder meeting, conditioned on his continued service through the vesting date.
Definitive Healthcare Corp. reported the results of its 2026 annual meeting of stockholders. Shareholders elected three Class II directors to terms running until the 2029 annual meeting, with each nominee receiving over 114 million votes in favor and sizable broker non-votes.
Stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 130,745,809 votes for and limited opposition. They also approved increasing the shares authorized under the 2021 Equity Incentive Plan by 15,000,000, taking the plan reserve from 30,972,789 to 45,972,789, and supported, on a non-binding advisory basis, the compensation of named executive officers.
Definitive Healthcare Corp.'s Chief Financial Officer Casey Heller reported a routine share disposition tied to taxes rather than a market trade. The company withheld 164,377 shares of Class A common stock at an effective value of $0.99 per share to cover Heller's tax obligations from vesting restricted stock units. After this tax-withholding transaction, Heller directly holds 1,841,476 shares of Class A common stock, indicating a substantial remaining equity position in the company.
Definitive Healthcare Corp. reported that CEO Kevin Coop had shares withheld to cover taxes tied to restricted stock units vesting. The Form 4 shows a tax-withholding disposition of 66,050 shares of Class A Common Stock at $0.99 per share, with no open-market trade. After this transaction, Coop is reported as directly owning 5,012,822 Class A shares, so the withheld amount is a small portion of his overall holdings and reflects a compensation-related event rather than a discretionary stock sale.